These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20371720)

  • 1. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
    Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
    Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
    Taguchi F; Koh Y; Koizumi F; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2004 Dec; 95(12):984-9. PubMed ID: 15596048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.
    Yang Y; Ikezoe T; Nishioka C; Taguchi T; Zhu WG; Koeffler HP; Taguchi H
    Cancer Sci; 2006 Dec; 97(12):1404-9. PubMed ID: 16995874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target.
    Zalcman N; Gutreiman M; Shahar T; Weller M; Lavon I
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III.
    Fukai J; Nishio K; Itakura T; Koizumi F
    Cancer Sci; 2008 Oct; 99(10):2062-9. PubMed ID: 19016767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
    Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA
    Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZD6474--clinical experience to date.
    Heymach JV
    Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S14-20. PubMed ID: 15928653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.
    Qi Q; He K; Yoo MH; Chan CB; Liu X; Zhang Z; Olson JJ; Xiao G; Wang L; Mao H; Fu H; Tao H; Ramalingam SS; Sun SY; Mischel PS; Ye K
    J Biol Chem; 2012 Feb; 287(9):6113-27. PubMed ID: 22215664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma.
    Pedron S; Hanselman JS; Schroeder MA; Sarkaria JN; Harley BAC
    Adv Healthc Mater; 2017 Nov; 6(21):. PubMed ID: 28766870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
    Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
    Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.
    Meng J; Liu Y; Gao S; Lin S; Gu X; Pomper MG; Wang PC; Shan L
    Cancer Biol Ther; 2015; 16(12):1764-74. PubMed ID: 26467217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
    Ohno M; Natsume A; Ichiro Iwami K; Iwamizu H; Noritake K; Ito D; Toi Y; Ito M; Motomura K; Yoshida J; Yoshikawa K; Wakabayashi T
    Cancer Sci; 2010 Dec; 101(12):2518-24. PubMed ID: 20880333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration.
    Banisadr A; Eick M; Beri P; Parisian AD; Yeoman B; Placone JK; Engler AJ; Furnari F
    J Cell Sci; 2020 Dec; 133(24):. PubMed ID: 33243756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saccharina japonica Extract Suppresses Stemness of Glioma Stem Cells by Degrading Epidermal Growth Factor Receptor/Epidermal Growth Factor Receptor Variant III.
    Kim SY; Kim JY; Shin WS; Lee SJ; Chi SG; Lee JY; Park MJ
    J Med Food; 2018 May; 21(5):496-505. PubMed ID: 29648968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMED2 promotes glioma tumorigenesis by being involved in EGFR recycling transport.
    Sun C; Zhang Y; Wang Z; Chen J; Zhang J; Gu Y
    Int J Biol Macromol; 2024 Mar; 262(Pt 2):130055. PubMed ID: 38354922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large and small extracellular vesicles released by glioma cells
    Yekula A; Minciacchi VR; Morello M; Shao H; Park Y; Zhang X; Muralidharan K; Freeman MR; Weissleder R; Lee H; Carter B; Breakefield XO; Di Vizio D; Balaj L
    J Extracell Vesicles; 2020; 9(1):1689784. PubMed ID: 31839905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer.
    Flanigan J; Deshpande H; Gettinger S
    Biologics; 2010 Sep; 4():237-43. PubMed ID: 20859451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma.
    Noguchi S; Yasumura M
    Vet Res Commun; 2023 Dec; 47(4):2207-2213. PubMed ID: 36991174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X; Pastan I; Bigner DD; Chandramohan V
    Receptors Clin Investig; 2016; 3(4):. PubMed ID: 28286803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.